Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Molecular Diagnostics - Technologies, Markets and Companies
Benefits of this report
This report has evolved during the past ten years, profiting from feedback by numerous readers and experts.
The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.
Includes profiles of 257 companies, the largest number in any report on this topic.
The text is supplemented by 81 tables and 12 figures and 450 references are appended.
Who should read this report?
Chief executive officers of molecular diagnostic companies.
Business development executives of pharmaceutical and biotechnology companies.
Executives of companies involved in developing integration of diagnosis and treatment as well as those interested in personalized medicine.
Officers of genomic and proteomic companies interested in diagnostic technologies.
Research scientists involved in application of molecular diagnostic technologies.
Planners of healthcare services.
Summary
This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, biochips, nanotechnology and proteomic technologies.
Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for for point-of-care and biowarfare agents such as anthrax.
The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 500 companies have been identified to be involved in developing molecular diagnostics and 257 of these are profiled in the report along with tabulation of 576 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.
The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2007 according to technologies, applications and geographical regions. Forecasts are made up to 2017. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.
This report was first published as DNA Diagnostics in 1995 by PJB Publications, UK. It was updated in 1997 as Molecular Diagnostics and the next edition, Molecular Diagnostics II, was published by Decision Resources Inc in 1999. All the three versions of the reports were well accepted and sold widely.The report has been rewritten several times since then.
Table of contents
Part I: Technologies, Ethics & Regulations
Basics of Molecular Diagnostics
Molecular Diagnostic Technologies
Biochips, Biosensors and Molecular Labels
Proteomic Technologies for Molecular Diagnostics
Molecular Diagnosis of Genetic Disorders
Molecular Diagnosis of Infections
Molecular Diagnosis of Cancer
Molecular Diagnostics in Biopharmaceutical Industry and Healthcare
Molecular Diagnostics in Forensic Medicine and Biological Warfare
Ethics, Patents and Regulatory Issues
References
Part II: Markets & Companies
Markets for Molecular Diagnostics
Molecular Diagnostic Companies
May 2008. 802 Pages. 81 Tables, 12 Figures, 257 Companies profiled, 576 Alliances listed and 450 References.
Table of Contents
Full Table of Content - Part 1 (PDF)
Price
PDF Format $4,500.00
Print Format $5,000.00
PDF + Print $5,500.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.